Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001635088-26-000073
Filing Date
2026-06-29
Accepted
2026-06-29 18:23:06
Documents
1
Period of Report
2026-06-25

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1782771783.html 4  
1 FORM 4 wk-form4_1782771783.xml 4 12570
  Complete submission text file 0001635088-26-000073.txt   14232
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Issuer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON United Kingdom SW1H 0DB
Business Address
Sukhatme Mayukh (Reporting) CIK: 0001750050 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40782 | Film No.: 261137325